Philip Adamson, MD, MSc, is the chief medical officer of CVRx.

Philip Adamson, MD, MSc

Heart failure management has long been triggered by symptoms, yet the underlying neurohormonal cascade driving disease progression often begins well before congestion or breathlessness appear. Baroreflex activation therapy is drawing renewed attention as a way to intervene upstream, modulating the autonomic signaling the brain uses to interpret a failing heart as a circulatory emergency.

Moving the Needle in Medicine: Innovation, Leadership, and the Future of Heart Failure, With Philip Adamson, MD, MSc

, host Dr. Alex Hajduczok, MD, a cardiologist and heart failure specialist at Oklahoma Heart Institute, sits down with Dr. Philip Adamson, MD, MSc, chief medical officer of CVRx, to explore the personal experiences, mentors, and defining decisions that shaped his career in cardiovascular medicine.

Adamson traces his career from basic science and clinical investigation to device development and implementation science. Reflecting on his early research experiences, Adamson describes how an undergraduate laboratory project sparked a lifelong interest in scientific discovery while emphasizing the importance of intellectual curiosity, resilience, and remaining willing to challenge one’s own hypotheses throughout a research career.

Hajduczok and Adamson then examine the transformation of heart failure care over the past four decades, highlighting the shift from an era with limited therapeutic options to one defined by evidence-based, guideline-directed medical therapy. Adamson recounts the development of dedicated heart failure programs, the early skepticism surrounding subspecialization, and the growing recognition that multidisciplinary disease management is essential for improving long-term outcomes.

A major focus of the conversation centers on the development of implantable pulmonary artery pressure monitoring and the physiological principles underlying remote hemodynamic monitoring. Adamson reviews the lessons learned from early technologies that ultimately informed the creation of CardioMEMS, emphasizing that clinically useful monitoring must reflect meaningful pathophysiology, guide therapeutic intervention, assess treatment response, and provide sufficient lead time to prevent decompensation. Together, Hajduczok and Adamson also discuss implementation challenges, including clinician workflow, data management, and the emerging role of artificial intelligence and machine learning in transforming large volumes of physiologic data into actionable clinical insights.

The conversation also explores patient empowerment through remote monitoring technologies. Hajduczok and Adamson discuss how providing patients with actionable physiologic data may improve engagement, enhance self-management, and reduce heart failure hospitalizations by enabling earlier intervention before symptomatic congestion develops. They describe remote monitoring as an extension of chronic disease management, drawing parallels to continuous glucose monitoring in diabetes and emphasizing its potential to improve the scalability of care for increasingly complex heart failure populations.

Attention then shifts to autonomic modulation and baroreflex physiology, where Adamson reviews decades of work investigating baroreflex sensitivity as a predictor of cardiovascular outcomes and the rationale for neuromodulation therapies. He and Hajduczok discuss the evolution of Barostim therapy and its potential to influence multiple aspects of heart failure pathophysiology, including ventricular function, pulmonary pressures, autonomic balance, exercise capacity, and overall functional status. A recent patient experience serves to illustrate the systemic effects of neuromodulation, reinforcing the concept that heart failure requires therapies targeting interconnected physiologic networks rather than isolated mechanisms.

The episode concludes with reflections on scientific leadership, mentorship, and career development. Adamson encourages early-career investigators to embrace unexpected opportunities, learn from failure, maintain intellectual curiosity, and recognize that meaningful advances arise from continually questioning established knowledge. Together, Hajduczok and Adamson underscore that while research directions and professional roles evolve over time, a sustained commitment to improving the lives of patients with heart failure remains the driving force behind scientific innovation and clinical progress.

Editors’ Note: Hajduczok reports disclosures with CVRx, Edwards Lifesciences, and Impulse Dynamics. Adamson reports employment with CVRx.

Podcasts

Hear Philip Adamson, MD, MSc, discuss his path through heart failure and his work with Abbott and CVRx.

Philip Adamson, MD, MSc

Articles